Table 2.
Key assumptions for estimating commodity and delivery costs 1.
| MR Vaccine | N&S | MAP | |||||
|---|---|---|---|---|---|---|---|
| 1-Dose | 5-Dose | 10-Dose | Profile 1 | Profile 2 | Profile 3 | Profile 4 | |
| Estimated price per dose 2 | $2.48 | $0.90 | $0.72 | $1.29 | $1.29 | $2.11 | $2.92 |
| Doses per vial | 1 | 5 | 10 | 1 | 1 | 1 | 1 |
| Volume of the vaccine per dose (cm3), primary and secondary packaging | 21.09 | 4.218 | 2.109 | 3 | 20 | 8 | 3 |
| Human resource time use (in seconds) for vaccine administration | 48 | 35 | 21 | 20 | 200 | 120 | 20 |
| RI vaccine wastage rate | 5% | 15% | 40% | 1% | 1% | 1% | 1% |
| SIA vaccine wastage rate | 1% | 10% | 10% | 1% | 1% | 1% | 1% |
| Volume of diluent per dose (cm3) | 12.53 | 5.48 | 3.14 | 0 | 0 | 0 | 0 |
1 Each MAP profile was modeled separately with and without CTC use, where without CTC use assumes that MAP is in the cold chain for the entire supply chain until vaccine administration. In the commodity and delivery costs results, the average of the 5- and 10-dose vial presentations are presented together as the comparator presentation. 2 Prices per dose for N&S presentation were derived from the price benchmarking analysis.